Literature DB >> 7544051

Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120.

A L DeVico1, R Rahman, J Welch, R Crowley, P Lusso, M G Sarngadharan, R Pal.   

Abstract

The binding of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein, gp120, to its cell surface receptor, CD4, represents a molecular interaction involving distinct alterations in protein structure. Consequently, the pattern of epitopes presented on the gp120-CD4 complex should differ from those on free gp120. To investigate this concept, mice were immunized with covalently crosslinked complexes of viral HIV-1IIIBgp120 and soluble CD4. Two monoclonal antibodies (MoAbs) obtained from the immunized mice exhibited a novel epitope specificity. The MoAbs were marginally reactive with HIV-1IIIBgp120, highly reactive with gp120-CD4 complexes, and unreactive with soluble CD4. The same pattern of reactivity was seen in solid-phase assays using HIV-1(451)gp120. A similar specificity for complexes was evident in flow cytometry experiments, in which MoAb reactivity was dependent upon the attachment of gp120 to CD4-positive cells. In addition, MoAb reactivity was detected upon the interaction of CD4 receptors with purified HIV-1IIIB virions. Notably, seroantibodies from HIV-positive individuals competed for MoAb binding, indicating that the epitope is immunogenic in humans. The results demonstrated that crosslinked gp120-CD4 complexes elicit antibodies to cryptic gp120 epitopes that are exposed during infection in response to receptor binding. These findings may have important implications for the consideration of HIV envelope-receptor complexes as targets for virus neutralization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544051     DOI: 10.1006/viro.1995.1441

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody.

Authors:  S Lee; K Peden; D S Dimitrov; C C Broder; J Manischewitz; G Denisova; J M Gershoni; H Golding
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex.

Authors:  T R Fouts; R Tuskan; K Godfrey; M Reitz; D Hone; G K Lewis; A L DeVico
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Authors:  Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

4.  Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.

Authors:  Hua-Xin Liao; S Munir Alam; John R Mascola; James Robinson; Benjiang Ma; David C Montefiori; Maria Rhein; Laura L Sutherland; Richard Scearce; Barton F Haynes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies.

Authors:  Gilad Kaplan; Anna Roitburd-Berman; George K Lewis; Jonathan M Gershoni
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

6.  Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events.

Authors:  B J Doranz; S S Baik; R W Doms
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion.

Authors:  C M Finnegan; W Berg; G K Lewis; A L DeVico
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens.

Authors:  Anthony DeVico; Timothy Fouts; George K Lewis; Robert C Gallo; Karla Godfrey; Manhattan Charurat; Ilia Harris; Lindsey Galmin; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

9.  Inhibition of human immunodeficiency virus type 1 and vaccinia virus infection by a dominant negative factor of the interferon regulatory factor family expressed in monocytic cells.

Authors:  A M Thornton; R M Buller; A L DeVico; I M Wang; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.

Authors:  N M Stamatos; J R Mascola; V S Kalyanaraman; M K Louder; L M Frampton; D L Birx; T C VanCott
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.